Drug Type Small molecule drug |
Synonyms SHR 7390, SHR7390 |
Target |
Mechanism MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 17 Dec 2020 | |
Breast Cancer | Phase 2 | CN | 01 May 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Nov 2016 |
Phase 1 | 38 | (monotherapy trial) | mmvhwuzzgd(ipsrabbrcx) = icjmjevdml dynctoxixb (xwsdqisecj ) View more | Positive | 18 Nov 2022 | ||
(combination trial) | mmvhwuzzgd(ipsrabbrcx) = zlfawzzwzl dynctoxixb (xwsdqisecj ) View more | ||||||
NCT03182673 (ASCO2021) Manual | Phase 1 | - | SHR7390+camrelizumab | ddytyinhhd(xknujefych) = 1 grade 3 rash in 1 pt in the 0.5 mg cohort bmriotrruf (dpdmpbrluc ) View more | Positive | 28 May 2021 |